Company profile: Ariad Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of oncology medicines, focused on the discovery, development and commercialization of treatments for cancer patients, including Iclusig for certain types of leukemia targeting cancer cells with specific genetic mutations; based in Cambridge, Massachusetts.
Products and services
- Development and commercialization of cancer medicines: A global-scale effort that develops and commercializes breakthrough oncology products, delivering cancer medicines to patients through cohesive, purpose-driven operations
- Discovery of oncology medicines: An oncology-focused program that discovers breakthrough cancer medicines to transform patient lives, architected by a cohesive team committed to advancing therapies for cancer patients
- Iclusig: A mutation-targeted medication for certain types of leukemia that targets cancer cells with specific genetic mutations, offering focused treatment for the indicated patient population
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ariad Pharmaceuticals
Biovica
HQ: Sweden
Website
- Description: Provider of blood-based biomarker assays to help oncologists monitor cancer progression, including the DiviTum® TKa Test measuring cell proliferation from solid tumors, and pharma services offering TKa testing for dose-response information, patient selection, and treatment monitoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biovica company profile →
Koya Medical
HQ: United States
Website
- Description: Provider of breakthrough treatments for lymphedema and venous diseases, as a transformative healthcare company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Koya Medical company profile →
Deciphera Pharmaceuticals
HQ: United States
Website
- Description: Provider of kinase inhibitor–based cancer medicines leveraging a proprietary switch-control platform. Commercializes Ripretinib (QINLOCK) for advanced gastrointestinal stromal tumor after treatment with three or more kinase inhibitors, and develops a pipeline including Vimseltinib (CSF1R) for TGCT, DCC-3116 (ULK1/2) for cancers with RAS/RAF mutations, DCC-3084 (pan-RAF), and DCC-3009 (next‑gen KIT).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Deciphera Pharmaceuticals company profile →
Theraclone Sciences
HQ: United States
Website
- Description: Provider of novel therapeutic antibodies and an antibody discovery platform for infectious diseases and inflammation. Offers a comprehensive screening technology to identify rare human monoclonal antibodies, HIV broadly neutralizing fully human antibodies licensed to Gilead for HIV-cure regimens, and platform technology licensed to OncoResponse for oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theraclone Sciences company profile →
Empirica Therapeutics
HQ: Canada
Website
- Description: Provider of therapeutic drugs focused on adoptive immunotherapies targeting aggressive, treatment-resistant cancers, including glioblastoma and brain metastasis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Empirica Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ariad Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ariad Pharmaceuticals
2.2 - Growth funds investing in similar companies to Ariad Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ariad Pharmaceuticals
4.2 - Public trading comparable groups for Ariad Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →